EBV nanoparticle vaccine study for healthy adults
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This study tests two experimental vaccines against Epstein-Barr virus (EBV), the germ that causes mono. You may be able to join if you are a healthy adult aged 18–29 and haven't had an EBV vaccine before. The trial will check if the vaccines are safe and trigger an immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 29 years old.
- You need to be in good general health with normal blood tests.
- You must avoid live vaccines for 30 days before and after each dose (other vaccines like flu or COVID are okay with a 14-day gap).
- If you could become pregnant or get someone pregnant, you must use effective birth control from 30 days before your first shot until 60 days after your last shot.
- You cannot have ever participated in another EBV vaccine study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA vaccine designed to protect against the Epstein-Barr virus, which is a common virus that can cause illnesses like mono. It is for healthy young adults to see if the vaccine is safe and triggers a good immune response.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests an experimental mRNA vaccine (mRNA-1189) to see if it can prevent Epstein-Barr virus (EBV) infection. It is for healthy adults 18 to 30 years old.
This study tests two experimental vaccines (V350A and V350B) designed to prevent Epstein-Barr virus infection. It is looking for healthy adolescents and adults to see if the vaccines are safe and produce a good immune response.
This study looks at how the immune system’s antibodies behave after a first-time EBV infection, including whether they mistakenly react with the body’s own tissues. You might be offered a chance to help doctors understand why some people get longer or more intense symptoms from infectious mononucleosis.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
Hear when a new EBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.